Neuroprotection does not work!

Stroke

Volumn 39, Issue 2, 2008, Pages 523-524

  Röther, Joachim ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Neuroprotection

Indexed keywords

ALTEPLASE; AMPA RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; CALCIUM ANTAGONIST; DESMOTEPLASE; DIZOCILPINE; GLYCINE RECEPTOR ANTAGONIST; NEUROPROTECTIVE AGENT; POTASSIUM CHANNEL BLOCKING AGENT; SCAVENGER; SEROTONIN ANTAGONIST; SODIUM CHANNEL BLOCKING AGENT;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN CORTEX; BRAIN ISCHEMIA; BRAIN PERFUSION; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; DROWSINESS; DRUG EFFICACY; HUMAN; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REPERFUSION; STROKE; ANIMAL; NOTE; TREATMENT FAILURE;

ANIMALS; BRAIN ISCHEMIA; HUMANS; NEUROPROTECTIVE AGENTS; STROKE; TREATMENT FAILURE;

EID: 39349100371     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.494799     Document Type: Article

References (8)

1. Gill R, Foster AC, Woodruff GN. MK-801 is neuroprotective in gerbils when administered during the post-ischaemic period. Neuroscience. 1988;25:847-855.
2. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30:2752-2758.
3. Fisher M, Hanley DF, Howard G, Jauch EC, Warach S. Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes. Stroke. 2007;38:245-248.
4. Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo JM, Ford GA. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive doseresponse study of UK-279,276 in acute ischemic stroke. Stroke. 2003;34:2543-2548.
5. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-600.
6. Warach S, Pettigrew LC, Dashe JF, Pullicino P, Lefkowitz DM, Sabounjian L, Harnett K, Schwiderski U, Gammans R. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann Neurol. 2000;48:713-722.
7. Spudich A, Kilic E, Xing H, Kilic U, Rentsch KM, Wunderli-Allenspach H, Bassetti CL, Hermann DM. Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat Neurosci. 2006;9:487-488.
8. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36:66-73.